Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 5/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.50 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8544793 | 1.00 | GSK3B (0.59) | GSK3BSMN1; SMN2PIM1CGASADAMTS5 | |
| SCHEMBL1520384 | 0.83 | PIM1 (0.56) | GSK3BSMN1; SMN2PIM1ALDH1A1MAPT | |
| SCHEMBL1520385 | 0.83 | PIM1 (0.56) | GSK3BSMN1; SMN2PIM1ALDH1A1MAPT | |
| SCHEMBL1520382 | 0.83 | PIM1 (0.56) | GSK3BSMN1; SMN2PIM1ALDH1A1MAPT | |
| SCHEMBL8209251 | 0.74 | GSK3B (1.00) | GSK3BSMN1; SMN2CGASMAPTRAB9A | |
| SCHEMBL8209256 | 0.74 | GSK3B (1.00) | GSK3BSMN1; SMN2CGASMAPTRAB9A | |
| SCHEMBL8209254 | 0.74 | GSK3B (1.00) | GSK3BSMN1; SMN2CGASMAPTRAB9A | |
| SCHEMBL8616104 | 0.74 | GSK3B (0.66) | GSK3BSMN1; SMN2PIM1ADAMTS5ALDH1A1 | |
| SCHEMBL1250019 | 0.70 | GSK3B (1.00) | GSK3BSMN1; SMN2PIM1MAPTHPGD | |
| SCHEMBL13848481 | 0.70 | KMT2A (0.60) | GSK3BSMN1; SMN2PIM1ADAMTS5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORP (US) | 2026-01-29 | — | — | US | disclosed |
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-10-07 | — | — | US | disclosed |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2024-05-16 | — | — | US | disclosed |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | PROMEGA CORPORATION (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | PROMEGA CORPORATION | 2022-11-03 | — | — | US | disclosed |
| EP-0695749-B1 | Process for the selective hydrogenation of activated, ethylenically unsaturated compounds | RUETGERS ORGANICS GMBH (DE) | 1998-11-25 | — | — | EP | disclosed |
| EP-0695749-A1 | Process for the selective hydrogenation of activated, ethylenically unsaturated compounds | RÜTGERSWERKE AKTIENGESELLSCHAFT (DE) | 1996-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435354-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | GSK3B 2946/4885SMN1; SMN2 1150/4885PIM1 3441/4885 |
| US-20220348983-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | GSK3B 2946/4885SMN1; SMN2 1150/4885PIM1 3441/4885 |
| US-20240158831-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, UPF1, LUC7L2 | GSK3B 2946/4885SMN1; SMN2 1150/4885PIM1 3441/4885 |
| US-11661623-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | GSK3B 2946/4885SMN1; SMN2 1150/4885PIM1 3441/4885 |
| US-12215375-B2 | Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use | RNGTT, UPF1, LUC7L2 | GSK3B 2946/4885SMN1; SMN2 1150/4885PIM1 3441/4885 |
| US-20260028662-A1 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | RNGTT, VIP, PREP | GSK3B 764/4885SMN1; SMN2 1912/4885PIM1 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.